Spiral Therapeutics Announces CEO’s Participation at the 3rd Inner Ear Disorders Therapeutics Summit in Boston, MA
SOUTH SAN FRANCISCO, Calif., Aug. 14, 2023 — Spiral Therapeutics, Inc. (“Spiral”), a clinical-stage company delivering therapies for inner ear disorders, is proud to announce the participation of its Chief Executive Officer, Hugo Peris, at the forthcoming 3rd Inner Ear Disorders Therapeutics Summit. The event is scheduled to take place from August 29-31, 2023, in […]
Spiral Therapeutics Acquires Otonomy Assets to Boost Inner Ear Disorders Pipeline and Appoints Industry Leaders to Board
SOUTH SAN FRANCISCO, Calif., March 29, 2023 — Spiral Therapeutics, Inc. (“Spiral”), a clinical-stage company focused on delivering therapies for inner ear disorders, announced today the completion of its acquisition of selected assets from Otonomy, Inc. (“Otonomy”), following the stockholder approval of Otonomy’s dissolution. The transaction includes preclinical and clinical data related to OTO-104 (OTIVIDEX), a sustained-exposure […]
Spiral Therapeutics Announces SPT-2101 Presentation at the 15th ASOHNS Congress in Brisbane, Australia
SOUTH SAN FRANCISCO, Calif., Mar. 06, 2023 — Spiral Therapeutics, Inc. (“Spiral”), a clinical-stage company delivering therapies for inner ear disorders, today announced a presentation at the upcoming 15th Asia Oceania ORL-HNS Congress, to be held March 8-12, 2023 in Brisbane, Australia. Dr. Jafri Kuthubutheen will join the session “Vestibular: Surgical vertigo” for an oral […]